Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.
Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...
The US Health Resources and Services Administration (HRSA) revealed the initial nine drugs to be included in the 340B rebate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback